EP1515748A2 - Anti-estrogen and immune modulator combinations for treating breast cancer - Google Patents
Anti-estrogen and immune modulator combinations for treating breast cancerInfo
- Publication number
- EP1515748A2 EP1515748A2 EP02793936A EP02793936A EP1515748A2 EP 1515748 A2 EP1515748 A2 EP 1515748A2 EP 02793936 A EP02793936 A EP 02793936A EP 02793936 A EP02793936 A EP 02793936A EP 1515748 A2 EP1515748 A2 EP 1515748A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- receptor
- estrogen
- immune
- cancer
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001833 anti-estrogenic effect Effects 0.000 title claims abstract description 53
- 239000000328 estrogen antagonist Substances 0.000 title claims abstract description 51
- 229940046836 anti-estrogen Drugs 0.000 title claims abstract description 45
- 206010006187 Breast cancer Diseases 0.000 title claims description 68
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 60
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 44
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 210000000481 breast Anatomy 0.000 claims abstract description 26
- 230000010261 cell growth Effects 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000003112 inhibitor Substances 0.000 claims abstract description 14
- 239000003886 aromatase inhibitor Substances 0.000 claims abstract description 13
- 239000003270 steroid hormone Substances 0.000 claims abstract description 13
- 230000005764 inhibitory process Effects 0.000 claims abstract description 11
- 210000002307 prostate Anatomy 0.000 claims abstract description 9
- 230000027455 binding Effects 0.000 claims abstract description 8
- 210000001072 colon Anatomy 0.000 claims abstract description 7
- 229940036555 thyroid hormone Drugs 0.000 claims abstract description 6
- 239000005495 thyroid hormone Substances 0.000 claims abstract description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 159
- 229960001603 tamoxifen Drugs 0.000 claims description 79
- 239000000262 estrogen Substances 0.000 claims description 64
- 229940011871 estrogen Drugs 0.000 claims description 63
- 108020003175 receptors Proteins 0.000 claims description 46
- 102000005962 receptors Human genes 0.000 claims description 45
- KDYQVUUCWUPJGE-UHFFFAOYSA-N Ethamoxytriphetol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC=CC=1)CC1=CC=C(OC)C=C1 KDYQVUUCWUPJGE-UHFFFAOYSA-N 0.000 claims description 29
- 229940088597 hormone Drugs 0.000 claims description 25
- 239000005556 hormone Substances 0.000 claims description 25
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 19
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 15
- 230000012010 growth Effects 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002751 imiquimod Drugs 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 7
- 230000002611 ovarian Effects 0.000 claims description 7
- 239000000186 progesterone Substances 0.000 claims description 7
- 229960003387 progesterone Drugs 0.000 claims description 7
- 108010046644 Polymeric Immunoglobulin Receptors Proteins 0.000 claims description 6
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 5
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- OEKMGABCSLYWOP-DHUJRADRSA-N [4-[(2s)-7-(2,2-dimethylpropanoyloxy)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-3-yl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(OC(=O)C(C)(C)C)C=C3O2)C)C=2C=CC(OC(=O)C(C)(C)C)=CC=2)=CC=C1OCCN1CCCCC1 OEKMGABCSLYWOP-DHUJRADRSA-N 0.000 claims description 4
- 230000001919 adrenal effect Effects 0.000 claims description 4
- 210000001989 nasopharynx Anatomy 0.000 claims description 4
- 230000001272 neurogenic effect Effects 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 210000003932 urinary bladder Anatomy 0.000 claims description 4
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 239000000960 hypophysis hormone Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102400001107 Secretory component Human genes 0.000 claims description 2
- FQJIZXBCOKNLMR-FTAPQOLWSA-N n-butyl-11-[(7r,8r,9s,13s,14s,16r,17r)-16-chloro-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-yl]-n-methylundecanamide Chemical compound C1C[C@]2(C)[C@@H](O)[C@H](Cl)C[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 FQJIZXBCOKNLMR-FTAPQOLWSA-N 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 229960005026 toremifene Drugs 0.000 claims description 2
- 229940123965 Immunoglobulin inhibitor Drugs 0.000 claims 11
- 230000016784 immunoglobulin production Effects 0.000 claims 3
- 102000006877 Pituitary Hormones Human genes 0.000 claims 2
- 108010047386 Pituitary Hormones Proteins 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- -1 ICI 16384 Chemical compound 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000034918 positive regulation of cell growth Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 abstract description 9
- 229940046844 aromatase inhibitors Drugs 0.000 abstract description 8
- 210000001672 ovary Anatomy 0.000 abstract description 6
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 36
- 230000000694 effects Effects 0.000 description 27
- 108010038795 estrogen receptors Proteins 0.000 description 20
- 210000000987 immune system Anatomy 0.000 description 19
- 230000003278 mimic effect Effects 0.000 description 18
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 17
- 102100038595 Estrogen receptor Human genes 0.000 description 17
- 229960002847 prasterone Drugs 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 230000003248 secreting effect Effects 0.000 description 15
- 230000009471 action Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 9
- 229960001614 levamisole Drugs 0.000 description 9
- 230000035935 pregnancy Effects 0.000 description 9
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 102000014654 Aromatase Human genes 0.000 description 7
- 108010078554 Aromatase Proteins 0.000 description 7
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000003098 androgen Substances 0.000 description 5
- 229940030486 androgens Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008102 immune modulation Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 201000010255 female reproductive organ cancer Diseases 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 3
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000005969 steroid hormone receptors Human genes 0.000 description 3
- 108020003113 steroid hormone receptors Proteins 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- BVVFOLSZMQVDKV-KXQIQQEYSA-N ICI-164384 Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 BVVFOLSZMQVDKV-KXQIQQEYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960003608 clomifene Drugs 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- 229960001348 estriol Drugs 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000008975 immunomodulatory function Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940106582 estrogenic substances Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000007483 microbial process Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Definitions
- the present invention generally relates to methods and compositions for the use of tamoxifen and other anti-estrogenic compounds in combination with immune modulator agents (immunoglobulin inhibitors of estrogen responsive cancer cell growth), to treat or prevent breast cancer.
- immune modulator agents immunoglobulin inhibitors of estrogen responsive cancer cell growth
- estrone [3-hydroxy-estra-l,3,5(10)-trien-17-one] ( ⁇ ⁇ ) from human pregnancy urine (3,12).
- Estradiol-17j8 [estra-l,3,5(10)-triene-3, 17/3-diol] (E 2 ) was also isolated from sow follicular fluid (4).
- the remaining major estrogen, estriol [1,3,5- estratriene-3, 16 (X, 17 ⁇ -triol] (E 3 ) has also been defined.
- E 2 > ⁇ ⁇ »» E 3 (5) The relative potency of these three hormones is known today to be E 2 > ⁇ ⁇ »» E 3 (5).
- E 2 and E 1 are in the main considered the most physiologically relevant (6-9).
- Estriol is most likely relevant during pregnancy when the maternal plasma level is significantly elevated (10).
- maternal E 3 is formed primarily as a placental conversion product of a steroid produced by the fetal adrenals.
- Breast cancers are not uncommon during pregnancy (18,22-25). However, all three estrogens are increased in pregnancy (10). In pregnant women, breast cancer is often diagnosed at a later stage (18). It may be that the elevated hormones during this time cause growth of developing breast cancer cells in pregnant females (19). Clearly, however, pregnancy has opposing effects on breast cancer development.
- Estrogen sulfates and glucuronides are cleaved by intestinal flora to regenerate free estrogens that again appear in the plasma and urine via the enterohepatic circulation (36).
- a high fiber-low fat diet tends to decrease this process.
- Other intestinal microbial processes also convert inactive estrogen metabolites to active steroid hormones (37). Thus, recycling of estrogens is entirely possible.
- the sites of synthesis of estrogenic substances in the body are not limited to the ovary (13). While it is understood with premenopausal women that estrogens are primarily of ovarian origin, this is not the case in postmenopausal females (38-41). The question is "what is the origin(s) of estrogens in the postmenopausal female”? This is important because breast cancer rates are much higher in postmenopausal women (42) even though estrogen levels are declining Nonetheless, 80 or 90% of breast cancers in postmenopausal women are ER + (43), implying they are estrogen growth promoted.
- aromatase is present in breast tissue and cells and represents an "intracrine" source of stimulating steroid hormone (49). Because of the major role of aromatase in generating breast cancer promoting estrogens in postmenopausal women, a series of aromatase inhibitors has been developed and are now in use as pharmaceutical products or are in and clinical trials as breast cancer treatments (41).
- ER ⁇ was acknowledged as the only estrogen receptor, variants of it were being identified (55,56).
- ER/3 another type of estrogen receptor, designated ER/3, was cloned from a rat prostate and ovary (57). This initiated a boom of new activity to define the function and properties of ER/3 (58,60,61). Indeed, the results suggest that the role of estrogens in male accessory organ function deserves renewed study (58). The characteristics and properties of ERc versus ER/3 have been reviewed (58,61,63). For the purposes of this disclosure, it should be noted that the binding affinities of both receptors are approximately equal (61). This was expected. However, one startling fact has surfaced.
- ER ⁇ The characteristics of ER ⁇ are that it binds estrogens with 10 to 100-fold higher affinities than ERc or ER/3. Furthermore, it is proposed that this receptor is a new gene that is expressed in all estrogen growth responsive target tissues. Data obtained indicate that this receptor is present in eight well-known estrogen responsive tumor cell lines derived from four tissues and three species including human (32-34,53,54).
- the hypersensitive mutated receptor (67) is present in all ER + cell types including those from rat mammary and rat pituitary tumors as well as from estrogen-induced kidney tumor cells from Syrian hamster (32-34). This means that a specific mechanism must exist for formation of this receptor in target tissue cells, or that this receptor is derived from a new gene. The latter possibility implies that the response of ER + cells to very low concentrations of E 2 involves the proposed new ER ⁇ (53,54).
- SERMs selective estrogen receptor modulators
- the mechanism of action of these drugs is to block the growth promoting action of estrogens at the cellular/receptor level, no matter whether the sex steroid hormones are delivered systemically or formed locally in breast tissue via aromatase action on adrenal steroid precursors. Hence, these drugs are classified as anti- estrogens.
- anti-estrogens are thought to interfere with the binding of natural estrogens to the growth promoting estrogen receptor(s).
- the first potent anti-estrogen developed 1958 was MER-25 or ethamoxytriphetol
- Tamoxifen is classified as a "mixed” anti-estrogen because it displays both antagonistic properties (i.e. inhibits breast cancer cell growth) and agnostic properties (i.e. stimulates endometrial cell growth and tumor development) (71).
- the action of the anti-estrogens is reversed by lower concentrations of the natural estrogens (53,54).
- the affinity of tamoxifen for the estrogen receptor is 10 to 100-fold less than that of E . This is commonly recognized throughout the endocrine cancer field. It is therefore useful to suppress natural estrogens along with application of tamoxifen treatment. This fact is often not recognized clinically. Postmenopausal women are not completely devoid of estrogens. Tamoxifen effectiveness is reduced by residual estrogenic steroid hormones. It is also reduced by the tamoxifen induced elevation of DHEA, E and Ei (81- 83). This is an unfortunate side effect of using this drug alone.
- tamoxifen was shown to mimic the inhibition caused by IgA or IgM in the complete absence of estrogens. This new tamoxifen function represents a clear departure from previous thought concerning how this "mixed function" anti-estrogen acts.
- this anti-estrogen was capable of acting by mimicking the growth inhibitory effects of the natural secretory immune system immunoglobulins IgA, IgM and IgGl.
- Another class of anti-estrogens is defined as "pure” because they only affect growth via interaction with estrogen receptors (71).
- the pure anti-estrogens were discovered about 15 years ago (74).
- Two of these, ICI 164384 and ICI 182780 are in clinical trials.
- tamoxifen resistance develops with time (75)
- the pure anti-estrogens are thought to be useful as second-line therapies after tamoxifen failure (71).
- pure anti-estrogens are thought useful because they cause no increase in endometrial cancer (71).
- compositions and methods which advantageously employ compounds having a newly defined immune modulating function, or which have the ability to mimic that immune modulating function, or a combination of such compounds.
- immune mimic e.g., anti-proliferative function
- immune modulating e.g., anti-proliferative function
- immuno suppressor refer in most instances to the newly identified cancer cell growth (i.e., proliferation) inhibitory effect of the secretory immune system (i.e., dimeric/polymeric IgA and pentameric IgM) that is mediated by a newly identified Poly-Ig receptor or Poly-Ig-like receptor (also classified as an Fc-like receptor), and not to the usual antibody/antigen recognition based immune function of the immune system.
- the terms "immune modulation” or “immune enhancement” refer especially to the modulation or enhancement of these cell growth inhibitory immunoglobulins of the secretory immune system.
- immuno mimic refers to a substance (e.g., tamoxifen) that can function in a similar manner to an irnmunoglobulin inhibitor of cell growth.
- natural immune inhibition e.g., tamoxifen
- immune enhancer e.g., tamoxifen
- immune modulator e.g., immune modulator
- immune system e.g., immune therapy
- response e.g., an indication has been made in appropriate instances whether a conventional definition or the "new" meaning, or both, is intended.
- tamoxifen is used as a breast cancer treatment taking advantage of its newly identified function as an immune mimic instead of an anti-estrogen. That tamoxifen is a mixed anti-estrogen is well known. It not only binds to cellular estrogen receptors, but it also has other unrelated sites of cellular action. This new function for tamoxifen makes possible new combination therapies as well as new diagnostic methods to determine whether breast or other mucosal origin cancers are expected to be susceptible to these therapies. It is concluded that combination therapies of tamoxifen and the "pure" anti-estrogens may be more effective than either class of drug alone.
- Tamoxifen treatment alone has several positive aspects as well as a number of negatives.
- the negatives can be overcome by placing this well known anti-estrogen in combinations with other compounds.
- the preferred combinations represent those that permit the mixture to act more effectively than the individual component alone.
- the combinations may include two or more breast cancer treatment drugs, some of which are classified as "pure" anti-estrogens while others are defined as immune modulators.
- a new tamoxifen- based therapeutic method in which tamoxifen acts as an immune inhibitor mimic ("immune mimic").
- the method preferably includes employing a new diagnostic test to identify breast cancer cells expressing the inhibitor-mediating receptor (a Poly-Ig receptor or Poly-Ig like receptor), also classified as an Fc-like receptor, as an indication of sensitivity to cell growth inhibition by tamoxifen.
- a new diagnostic test to identify breast cancer cells expressing the inhibitor-mediating receptor (a Poly-Ig receptor or Poly-Ig like receptor), also classified as an Fc-like receptor, as an indication of sensitivity to cell growth inhibition by tamoxifen.
- the above-described tamoxifen therapy and diagnostic testing method is extended to mucosal cancers other than breast, including those of the prostate, colon, kidney, bladder, lung, pancreas, riasdphafynxV' ovai ehdo ' meMumJ vagina, and cervix.
- combinations of tamoxifen and aromatase inhibitors are employed to treat breast and gynecologic cancers.
- tamoxifen and a "pure" anti-estrogen compound are combined for treating breast and gynecologic cancers.
- compositions or therapeutic methods using chemically modified MER-25 to treat secretory immune system related cancers are provided.
- MER-25 or modified MER-25 is combined with progesterone or another hormone for treating breast cancer.
- Modified MER-25 or derivative compounds of MER-25 that may have satisfactory anti-estro genie or immune mimicking activity include methylated, alkylated, benzylated, halogenated, unsaturations, altered charge properties, and conformationally altered or stereoisomers of MER-25.
- combinations of tamoxifen and levamisole are used as an immune mimic and immune modulator to treat breast and other mucosal cancers, including colon cancer.
- combinations of tamoxifen and imiquimod are used as an immune mimic and immune modulator to treat breast and other mucosal cancers.
- tamoxifen and OK-432 (picibanil) are used as an immune mimic and immune modulator to treat breast and other mucosal cancers.
- compositions or therapeutic methods employing a combination of tamoxifen and DHEA (dehydroepiandrosterone) as an immune mimic and immune modulator to treat breast and other mucosal cancers.
- DHEA dehydroepiandrosterone
- a therapeutic method is provided in which tamoxifen and an Fc-like receptor gene therapy are used together to treat breast and other mucosal cancers.
- methods are provided for identifying anti- estrogenic compounds or for evaluating modified forms of existing compounds that might be more effective anti-estrogenic agents. These methods employ cell growth assays that, preferably, use certain serum-containing or serum-free media. In some embodiments, methods are provided for screening new compounds and for determining how combinations of compounds act on cells directly.
- Example 1 Tamoxifen Therapy and New Diagnostic Test for Immune Modulation Applications with Breast Cancer.
- the immunoglobulin action is mediated by a Poly-Ig receptor or a Poly-Ig-like receptor (also classified as an Fc-like receptor) that is identified by antibody raised against the extracellular five domains commonly called the "secretory component" (SC) (86).
- SC secretory component
- Those breast cancer cells expressing this Fc-like receptor are sensitive to inhibition by tamoxifen.
- Those cells not expressing the Fc-like receptor are not tamoxifen sensitive. Because the analysis can be done in completely serum-free defined medium (53,54) without estrogens, it is concluded that tamoxifen acts to mimic the Fc-like receptor mediated inhibition of cell growth by secretory immune system IgA and IgM.
- tamoxifen inhibits breast cancer cell growth not by interaction with the commonly recognized ER ⁇ or ER ⁇ but instead with the ER ⁇ (53,54).
- the direct histochemical measurement of ER ⁇ is expected to significantly increase the reliability of the decision to initiate anti-estrogen therapy. Further, the identification of ER ⁇ will permit reanalysis of existing and new compounds for anti-ER ⁇ activity. This approach can be expected to significantly advance how new SERMs are selected.
- Example 2 Tamoxifen Therapy and New Diagnostic Test for Immune Modulation Applications with other Mucosal Cancers including Prostate, Colon, Kidney, Bladder Lung, Pancreas, Nasopharynx, Ovarian, Endometrial, Vaginal and Cervical Cancer.
- Example 1 The analysis outlined in Example 1 will be used to determine the application of the tarnoxifen-based therapies to tumors arising from other mucosal tissues. Since the same secretory immune system is functional in all of the tissues (prostate, colon, kidney, bladder, lung, pancreas, nasopharynx, ovary, endometrium, vagina and cervix), the immunohistochemical analysis for SC detectable Fc-like receptor can be conducted. It has already been shown (89) that colon cancers progress through stages in which the SC is expressed (i.e. early differentiated tumors) to stages in which there is little or no detectable
- Tamoxifen and/or the combinations described will be used to treat Fc-like receptor positive (FcLR + ) tumors by the new protocols.
- FcLR + Fc-like receptor positive
- This new approach is expected to provide an expanded rationale for the use of tamoxifen to treat cancers not yet recognized as sensitive to this immune mimicking anti-estrogen.
- ER ⁇ As a test for ER ⁇ is developed, it can be used to further refine the tumor types susceptible to the new modes of tamoxifen combination therapies.
- Example 3 Combinations of Tamoxifen and Aromatase Inhibitors to Treat Breast and Gynecologic Cancers.
- tamoxifen sensitive e.g. endometrial, ovarian, vaginal, cervical and possibly prostate
- the combined tamoxifen-aromatase inhibitor therapy will have even broader application than is recognized today for either drug.
- Example 4 Combinations of Tamoxifen and Pure Anti-estrogens to Treat Breast and Gynecologic Cancers.
- MER-25 is an anti-estrogen by virtue of its inhibitory effects on estrogen target tissues. It also has the benefit that it does not interact with the estrogen receptor to accomplish its action (79).
- the advantage of MER-25 (or its modified forms) is that systemic or locally produced estrogens will not interfere. Thus, it can be used with ER pre- and postmenopausal women without concern for suppression of endogenous estrogen levels.
- MER-25 Early anti-estrogens such as MER-25 were by-passed by previous investigators because of their potency and adverse side effects. Although MER-25 has many desirable properties as an anti-estrogen, it has been reported to be too toxic for use in humans (78). However, if MER-25 and related compounds can be modified to achieve high levels of immune modulation without the serious side effects, this will open additional new avenues of breast cancer therapy. Accordingly, the chemical structure will be modified particularly in the O-C-C-N segment of the side chain to change the conformation and to prevent hydrogen bonding with neighboring hydroxyl groups (80). Only limited modifications in MER-25 have been sought (84). Other chemical changes in the structure are expected to attenuate the side effects considered most severe.
- Example 6 Combinations of MER-25 and Modified MER-25 with Progesterone and other Hormones.
- the undesirable side effects of MER-25 and chemically modified forms may also be attenuated by simultaneous treatment with progesterone.
- eating behavior and body weight regulation are affected by MER-25 (85).
- the administration of progesterone in rats corrected those side effects.
- at least some adverse properties in vivo may be due to altered hormonal influences.
- Administration of MER-25, and derivative compounds will be evaluated for causation of endocrine changes. Any changes identified will be corrected by simultaneous application of the appropriate hormone(s).
- MER-25 or one of its derivatives may influence, for example, pituitary hormone secretion, thyroid hormones, adrenal hormones and/or neurogenic amines. Cytokines are also included in this group. Such changes are expected to yield the severe side effects reported (78). Accordingly, a hormone derived from pituitary, adrenals or thyroid, or a cytokine or a neurogenic hormone may be administered together with MER-25 or a modified form of
- Example 7 Combination Tamoxifen and Levamisole as Immune Mimic and Immune Modulator to Treat Breast and Other Mucosal Cancers including Colon.
- Levamisole is known to be immunoregulatory at multiple levels (90). It is known to enhance an impaired immune system (91). Levamisole is currently used to treat Stage III colon cancer, and is recognized to be an immunostimulant, in the conventional sense, to assist the natural immune system (92). Drawing from the inventor's prior observations that increased secretory immunoglobulins IgA and IgM are not only cytostatic for breast cancer cells, but also cytotoxic, therapies that enhance immune function, increasing the presence of these secretory immunoglobulins in particular, are thus expected to be beneficial.
- levamisole will enhance the natural immune inhibition of breast cancer growth while tamoxifen offers an additional direct cellular effect.
- This combination approaches therapy from two different aspects of regulation.
- the use of levamisole to treat breast cancer is a new application, particularly when placed in combination with tamoxifen.
- Other components of preferred therapeutic compositions include aromatase inhibitors and/or "pure" anti-estrogens.
- Example 8 Combination Tamoxifen and Imiquimod as Immune Mimic and Immune Modulator to Treat Breast and Other Mucosal Cancers.
- Imiquimod is a conventional immune enhancer that is effective both as a topical preparation and when administered orally (93,94).
- the known use of this compound in breast cancer therapy is based on the action of interferon which is induced by imiquimod.
- the drug alone has only limited long term effects.
- Imiquimod therapy is expected to be highly effective in combination with an anti-estrogen such as tamoxifen or a new MER-25 derivative.
- the elevation of interferon affects the immune system as well as having potential effects directly on breast cancer cells.
- the addition of tamoxifen is expected to enhance any effects of interferon. This combination has three possible cytostatic/cytotoxic modes. First is the direct effect of the anti-estrogen.
- Second is an immune enhancing action of imiquimod, which is expected to include enhancement of the secretory immunoglobulin inhibitors of cancer cell growth.
- Third is the direct cytotoxic effect of interferon. This modality may be enhanced by measurement of the interferon receptor in breast specimens along with the Fc- like receptor.
- Example 9 Combination Tamoxifen and OK-432 (Picibanil) as Immune Mimic and Immune Modulator to Treat Breast and Other Mucosal Cancers.
- Ok-432 is a streptococcal preparation that has a strong immune modulating effect (95), employing the conventional meaning of "immune modulating," which generally refers to the antibody/antigen recognition function of the immune system.
- the active moiety of this preparation has not been identified. This preparation cannot be delivered orally. It has been used in breast cancer as intratumor injections (96). In those prior studies, the results were mixed but additional results from cell culture suggest that a combination with an anti- estrogen may have greater effect than OK-432 alone (97).
- Another route to administration of OK-432 is intrapleural administration, which was evaluated as a treatment for breast malignancy in pleural effusions (98). The results of the conventional immune therapy alone on disseminated breast cancer were encouraging.
- OK-432 with tamoxifen or an aromatase inhibitor will provide additional benefits and have anti-cancer effects beyond those that could have previously been predicted for OK-432 and tamoxifen.
- the role of OK-432 may be direct on tumor cells, or may involve a critical conventional immune response that then suppresses tumor" cell possible use of this preparation may be as an oral challenge to develop mucosal immunity as described (53,54). This route of administration and development of mucosal immunity represents an entirely new approach to the use of this immune modulator.
- Example 10 Combination Tamoxifen and DHEA (dehydroepiandrosterone) as Immune Mimic and Immune Modulator to Treat Breast and Other Mucosal Cancers.
- DHEA inhibited alone, and the "pure” anti-estrogen alone inhibited.
- Tamoxifen acts as a direct immune mimic, as described in Example 1, in addition to blocking the estrogen receptor.
- DHEA acts to stimulate the immune system and to deliver inhibitory androgens to breast cancer cells. It is believed that the conventional immune stimulatory action of DHEA will also serve to enhance the presence of the inhibitory secretory immunoglobulins. This multilevel approach is expected to be more effective than each of the compounds used alone. It is also expected to be more effective than use of a "pure" antiestrogen with only one mechanism of action.
- this combination may be even more effective when an aromatase inhibitor is added. Indeed, but applying the immunohistochemical classifications outlined above, along with determining the androgen receptor content, the combination therapy has a strong rational basis. Today androgen receptors are rarely measured in specimens of female breast cancer.
- Example 11 Combination Tamoxifen and Fc-like Receptor Gene therapy to Treat Breast and Other Mucosal Cancers.
- tamoxifen is effective only with cells that express the Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor
- introduction of this receptor into cells lacking immune control offers an entirely new approach to treatment of breast and other mucosal cancers.
- Viral vectors bearing the DNA coding for the full length functional Fc-like receptor can be used to transform disseminated cancer such that the tumor cells regain " se£si ⁇ i ⁇ i'ty , to ,l ⁇ am ⁇ x ⁇ fen.
- l Tnis' 1 ' is a significant concept because it permits activation of killing over a long duration and with multiple exposures to the virus plus tamoxifen.
- Example 12 Use of Serum-Containing and Serum-free Medium Assays to Define New Anti-estrogenic Compounds or to Modify Existing Compounds to More Effective Agents.
- Suitable cell lines for use in the assays are available from three different species and four different tissues (32-34), although another cell line that is capable of growing both in cell culture and when implanted into a compatible host could also be used.
- Use of steroid hormone depleted serum permits evaluation of its effect on the activity of the new compound. The presence of serum factors may alter activity and therefore indicate problems before initiation of time consuming and expensive animal testing.
- Pregnancy-associated breast cancer a case-control study in a young population with high fertility rate. Med Oncol 17:293-300. (23) Gwyn K & Theriault R (2001) Breast cancer during pregnancy. Oncology
- Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res
- Buzdar AU & Hortobagyi GN (1998) Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16:348-353.
- Buzdar AU & Hortobagyi G (1998) Update on endocrine therapy for breast cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33280101P | 2001-11-14 | 2001-11-14 | |
US332801P | 2001-11-14 | ||
PCT/US2002/036633 WO2003041654A2 (en) | 2001-11-14 | 2002-11-13 | Anti-estrogen and immune modulator combinations for treating breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1515748A2 true EP1515748A2 (en) | 2005-03-23 |
EP1515748A4 EP1515748A4 (en) | 2006-04-12 |
Family
ID=23299909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02793936A Withdrawn EP1515748A4 (en) | 2001-11-14 | 2002-11-13 | Anti-estrogen and immune modulator combinations for treating breast cancer |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1515748A4 (en) |
AU (1) | AU2002359401A1 (en) |
WO (1) | WO2003041654A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2857061A1 (en) | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859585A (en) * | 1986-04-17 | 1989-08-22 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of estrogens |
US4919937A (en) * | 1984-01-20 | 1990-04-24 | Mauvais Jarvis Pierre | Percutaneous administration of tamoxifen |
EP1366366A2 (en) * | 2000-05-10 | 2003-12-03 | David A. Sirbasku | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261787B1 (en) * | 1996-06-03 | 2001-07-17 | Case Western Reserve University | Bifunctional molecules for delivery of therapeutics |
-
2002
- 2002-11-13 EP EP02793936A patent/EP1515748A4/en not_active Withdrawn
- 2002-11-13 WO PCT/US2002/036633 patent/WO2003041654A2/en not_active Application Discontinuation
- 2002-11-13 AU AU2002359401A patent/AU2002359401A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4919937A (en) * | 1984-01-20 | 1990-04-24 | Mauvais Jarvis Pierre | Percutaneous administration of tamoxifen |
US4859585A (en) * | 1986-04-17 | 1989-08-22 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of estrogens |
EP1366366A2 (en) * | 2000-05-10 | 2003-12-03 | David A. Sirbasku | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
Non-Patent Citations (6)
Title |
---|
BRODIE A ET AL: "Aromatase inhibitors and their antitumor effects in model systems." ENDOCRINE-RELATED CANCER. JUN 1999, vol. 6, no. 2, June 1999 (1999-06), pages 205-210, XP002367011 ISSN: 1351-0088 * |
MCCORMICK DAVID L ET AL: "Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland" CANCER RESEARCH, vol. 56, no. 8, 1996, pages 1724-1726, XP008057031 ISSN: 0008-5472 * |
ROSSO R ET AL: "ADJUVANT SYSTEMIC TREATMENT OF RESECTABLE BREAST CANCER ELEVEN YEARS RESULTS OF A MONOINSTITUTIONAL CHEMO-HORMONE-IMMUNOTHERAPY TRIAL" ANTICANCER RESEARCH, vol. 9, no. 4, 1989, pages 1153-1156, XP008057015 ISSN: 0250-7005 * |
SAVAGE P ET AL: "A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily" BRITISH JOURNAL OF CANCER, vol. 74, no. 9, 1996, pages 1482-1486, XP002073161 ISSN: 0007-0920 * |
SAWAI K ET AL: "CHEMO-ENDOCRINE-IMMUNOTHERAPY WITH ADRIAMYCIN TAMOXIFEN AND OK-432 PICIBANIL FOR ADVANCED BREAST CANCER" JOURNAL OF JAPAN SOCIETY FOR CANCER THERAPY, vol. 19, no. 6, 1984, pages 1315-1320, XP008057016 ISSN: 0021-4671 * |
See also references of WO03041654A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003041654A2 (en) | 2003-05-22 |
EP1515748A4 (en) | 2006-04-12 |
WO2003041654A3 (en) | 2005-01-06 |
AU2002359401A1 (en) | 2003-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120121620A1 (en) | Anti-estrogen and immune modulator combinations for treating breast cancer | |
Taylor et al. | Speroff's clinical gynecologic endocrinology and infertility | |
Ishihara et al. | Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas | |
Han et al. | Treatment of human endometrial stromal cells with chorionic gonadotropin promotes their morphological and functional differentiation into decidua | |
Choi et al. | Expression pattern of endothelin system components and localization of smooth muscle cells in the human pre-ovulatory follicle | |
Sun et al. | A novel regulation of the oviductal glycoprotein gene expression by luteinizing hormone in bovine tubal epithelial cells | |
HUI ZHU et al. | Differential effects of progestin and relaxin on the synthesis and secretion of immunoreactive prolactin in long term culture of human endometrial stromal cells | |
Yan et al. | Testis epidermal growth factor and spermatogenesis | |
Makarevich et al. | The involvement of the GHIGF-I axis in the regulation of secretory activity by bovine oviduct epithelial cells | |
Camilletti et al. | New insights into progesterone actions on prolactin secretion and prolactinoma development | |
Ergul et al. | Endothelin-1 promotes steroidogenesis and stimulates protooncogene expression in transformed murine Leydig cells | |
Salzano et al. | Evaluation of factors involved in the failure of ovum capture in superovulated buffaloes | |
Sletten et al. | Expression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy | |
Feldman et al. | The effect of GH on estrogen receptor expression in the rat mammary gland | |
Hurst et al. | Estrogen receptors are present in human granulosa cells | |
Glace et al. | Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor α in rat uterine cells and tissues | |
Yahi et al. | Effects of dexamethasone on progesterone and estrogen profiles and uterine progesterone receptor localization during pregnancy in Sahel goat in Semi-Arid region | |
Kaminski et al. | The regulation of steroidogenesis by opioid peptides in porcine theca cells | |
Kunter et al. | Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells | |
Carpenter et al. | Ovarian regulation of endometrial gland morphogenesis and activin-follistatin system in the neonatal ovine uterus | |
Pereira et al. | Prostaglandin-mediated effects in early canine corpus luteum: in vivo effects on vascular and immune factors | |
Les Dees et al. | Alcohol and female puberty: The role of intraovarian systems | |
Li et al. | Coexpression of adrenomedullin and its receptors in the reproductive system of the rat: effects on steroid secretion in rat ovary | |
Danforth et al. | Tumour necrosis factor-α modulates oestradiol responsiveness of MCF-7 breast cancer cells in vitro | |
Somers et al. | Luteinization in primates is accompanied by loss of a 43-kilodalton adenosine 3', 5'-monophosphate response element-binding protein isoform |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIRBASKU, DAVID A. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SIRBASKU, DAVID A. |
|
17P | Request for examination filed |
Effective date: 20050615 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060224 |
|
17Q | First examination report despatched |
Effective date: 20070214 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIGNE BIOPHARMA INC. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SIRBASKU, DAVID A. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIGNE BIOPHARMA INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080710 |